Enzymotec Ltd. (ENZY) Posts Earnings Results, Misses Estimates By $0.04 EPS
Enzymotec Ltd. (NASDAQ:ENZY) released its quarterly earnings results on Wednesday. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.04. Enzymotec had a net margin of 8.37% and a return on equity of 3.12%. The business earned $11.40 million during the quarter, compared to the consensus estimate of $13.29 million. During the same period in the prior year, the firm earned $0.08 earnings per share. The business’s quarterly revenue was down 8.1% compared to the same quarter last year. Enzymotec updated its FY16 guidance to $0.17-0.19 EPS.
Shares of Enzymotec (NASDAQ:ENZY) opened at 5.50 on Thursday. The company has a market capitalization of $124.95 million, a PE ratio of 28.95 and a beta of 1.26. Enzymotec has a one year low of $5.65 and a one year high of $10.32. The firm’s 50-day moving average price is $6.91 and its 200 day moving average price is $7.80.
A number of research analysts recently issued reports on ENZY shares. Zacks Investment Research raised Enzymotec from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. Jefferies Group reissued a “hold” rating on shares of Enzymotec in a report on Thursday, August 4th.
Several hedge funds have recently added to or reduced their stakes in ENZY. Gagnon Securities LLC bought a new stake in Enzymotec during the second quarter valued at about $2,022,000. Gagnon Advisors LLC bought a new stake in Enzymotec during the second quarter valued at about $1,590,000. Laurion Capital Management LP bought a new stake in Enzymotec during the second quarter valued at about $1,572,000. Janus Capital Management LLC raised its stake in Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the period. Finally, TFS Capital LLC bought a new stake in Enzymotec during the second quarter valued at about $153,000. 36.19% of the stock is currently owned by institutional investors.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.